Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 9;23(12):6477.
doi: 10.3390/ijms23126477.

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era

Elisa De Carlo  1 , Elisa Bertoli  1   2 , Alessandro Del Conte  1 , Brigida Stanzione  1 , Eleonora Berto  1 , Alberto Revelant  3 , Michele Spina  1 , Alessandra Bearz  1
Affiliations
Review

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era

Elisa De Carlo et al. Int J Mol Sci. .

Abstract

The therapeutic landscape in patients with advanced non-small-cell lung cancer harboring oncogenic biomarkers has radically changed with the development of targeted therapies. Although lung cancers are known to frequently metastasize to the brain, oncogene-driven non-small-cell lung cancer patients show a higher incidence of both brain metastases at baseline and a further risk of central nervous system progression/relapse. Recently, a new generation of targeted agents, highly active in the central nervous system, has improved the control of intracranial disease. The intracranial activity of these drugs poses a crucial issue in determining the optimal management sequence in oncogene-addicted non-small-cell lung cancer patients with brain metastases, with a potential change of paradigm from primary brain irradiation to central nervous system penetrating targeted inhibitors.

Keywords: NSCLC; brain metastases; oncogenic biomarkers; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The neurological toxicities of brain radiotherapy.
Figure 2
Figure 2
Druggable molecular alterations with tailored treatments in oncogene-addicted NSCLC.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008;83:584–594. doi: 10.1016/S0025-6196(11)60735-0. - DOI - PMC - PubMed
    1. Waqar S.N., Samson P.P., Robinson C.G., Bradley J., Devarakonda S., Du L., Govindan R., Gao F., Puri V., Morgensztern D. Non-small-cell Lung Cancer with Brain Metastasis at Presentation. Clin. Lung Cancer. 2018;19:e373–e379. doi: 10.1016/j.cllc.2018.01.007. - DOI - PMC - PubMed
    1. Nishino M., Soejima K., Mitsudomi T. Brain metastases in oncogene-driven non-small cell lung cancer. Transl. Lung Cancer Res. 2019;8((Suppl. 3)):S298–S307. doi: 10.21037/tlcr.2019.05.15. - DOI - PMC - PubMed

MeSH terms

Substances